Since the introduction on the market in 1995 of Doxil, pegylated liposomal doxorubicin, liposomes have become one of the most clinically established drug delivery systems in nanomedicine. Among different liposomal formulations, cationic liposomes have attracted great attention because of their capacity to bind negatively charged nucleic acids to perform as non-viral gene delivery tools, and due to their potentials to fuse with cell membranes leading to a direct release of cargoes from liposomes into the cytoplasm and high drug delivery efficiency.